Abstract: Objective To evaluate the clinical efficacy and the toxicity of irinotecan combined with suitable-symptom nutritional supporting treatment for patients with advanced metastatic colorectal cancer who were intolerant of chemotherapy.Methods Twenty-four patients with tumor node metastases(TNM)stage Ⅳ advanced metastatic colorectal cancer were enrolled,and their Karnofsky performance status(KPS)score was 40-60.The observation group had 13 cases and the control group was 11 cases.The observation group was treated by irinotecan and suitable-symptom nutritional support; the control group was treated by suitable-symptom nutritional support.Results Tumor response rate of patients was 15.4%(2/13)in the observation group; the disease control rate was 53.8%(7/13).Survival rate of 1-year in the observation group was higher than that in the control group [53.8(7/13)vs 27.3(3/11),P < 0.05]; KPS increasing rate was higher than that of the control group [53.8(7/13)vs 27.3(3/11),P < 0.05].Adverse chemotherapy reaction was tolerable.Conclusions Disease control rate and 1-year survival rate in the observation group are significantly higher than those in the control group in advanced metastatic colorectal cancer.It can improve life quality.Patient tolerance and compliance are satisfactory.